Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued on Tuesday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Performance

NASDAQ BPTH opened at $0.18 on Tuesday. The business has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $0.80. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $7.67.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.